Ellsworth Advisors, LLC Gilead Sciences, Inc. Transaction History

Ellsworth Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 18, 2024	BUY	$73.27 - $83.09 $85,725 - $97,215	1,170 Added 11.31%	11,512 $932,000
Q3 2023 Oct 20, 2023	BUY	$73.94 - $80.67 $256,571 - $279,924	3,470 Added 50.49%	10,342 $775,000
Q2 2023 Jul 24, 2023	BUY	$76.01 - $86.7 $23,563 - $26,877	310 Added 4.72%	6,872 $529,000
Q1 2023 Apr 12, 2023	BUY	$77.31 - $88.08 $83,108 - $94,686	1,075 Added 19.59%	6,562 $544,000
Q4 2022 Jan 19, 2023	BUY	$62.32 - $89.47 $82,013 - $117,742	1,316 Added 31.55%	5,487 $0
Q3 2022 Oct 20, 2022	BUY	$59.54 - $68.01 $27,626 - $31,556	464 Added 12.52%	4,171 $257,000
Q2 2022 Jul 25, 2022	BUY	$57.72 - $65.01 $213,968 - $240,992	3,707 New	3,707 $229,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Ellsworth Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Ellsworth Advisors, LLC with notifications on news.